PAVmed, Inc. Stock News

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named a GenomeWeb 2026 Best Places to Work honoree, marking its second consecutive year in the annual program recognizing top workplaces across th...

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 11, 2026 in New York City. Lishan A...

Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck ® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), to...

Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial acceleration NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lu...

Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheck Proposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/NCHS ICD-10 ...

Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ® Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (N...

Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13, at 8:30 AM EDT NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subs...